Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial

FRANKFURT (Reuters) – Germany’s Merck KGaA has suffered a setback in the development of key cancer immunotherapy Bavencio, it having failed in a trial to prolong lives in gastric cancer patients when compared with standard chemotherapy.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *